fda nasal spray depression

FDA-Approved Nasal Spray For Depression Is 1st Of Its Kind

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Medscape · 7h

FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants.

Popular Science · 2d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Nasal spray to treat depression: Clinical trial conducted in Houston

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

ConsumerAffairs3d

FDA approves nasal spray drug to treat depression

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

FDA-Approved Nasal Spray For Depression Is 1st Of Its Kind

Trending now